DNAnexus, a cloud service that helps researchers access and analyze genomic data, raises $200M led by Blackstone, sources say at a $600M valuation
Michelle F Davis / Bloomberg :
Context & Ripple Effects
DNAnexus is following its June 2020 $100M Series G with a larger $200M round, but sources put the valuation at $600M — a striking discount to the healthcare-cloud peers that raised in the same window, with Clarify Health's $150M Series D reportedly clearing $1.4B and Reify Health hitting $4.8B+ weeks later.
The notable name on the check is Blackstone, which has been assembling a data-infrastructure portfolio: it bought Ancestry.com in 2020 and later put $300M into storage-and-analytics firm DDN at a $5B valuation. This round puts one of the largest private-equity shops directly inside the plumbing researchers use to store and analyze genomes.
First-order effects
- DNAnexus gains $200M of expansion capital for its genomics cloud platform, while accepting a reported $600M valuation well below what adjacent healthcare-analytics peers commanded in the same funding cycle.
- Blackstone takes a lead position in research-genomics infrastructure, adding to holdings that already span consumer genetics (Ancestry) and large-scale data storage for AI and HPC workloads (its later DDN investment).
Second-order effects
- Rivals in clinical-trial and health-analytics cloud software — Reify Health, Clarify Health — now compete against a DNAnexus backed by a firm with storage assets and consumer genetic data, pushing competition toward who can fund data-center-scale capacity rather than just software features.
- A PE-led round at a sub-peer valuation signals that genomic-computing companies may need to trade valuation for access to balance-sheet capital as their workloads grow more infrastructure-heavy.
Third-order effects
- With 23andMe auctioning its DNA dataset to bidders including Regeneron, genomic data itself is becoming a tradeable asset — and firms like Blackstone are positioning to own the storage layer, the analysis layer, and potentially the source data at once.
- If private equity keeps displacing venture capital as the funding source for scientific data platforms, the industry drifts toward fewer, more consolidated owners of research infrastructure — a structural shift whose pace depends on whether discounted rounds like this one prove the exception or the template.
The trend: Private equity is moving down the genomics stack, buying not just datasets but the cloud infrastructure that stores and analyzes them.